Recombinant human interferon alpha D in HSV-1 recurrence in the rabbit

Area of Science:

• Ophthalmology
• Virology
• Immunology

Background:

• Herpes simplex virus type-1 (HSV-1) reactivation can cause ocular infections.
• Interferons are cytokines with antiviral properties.
• Recombinant interferons are explored for therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of recombinant human interferon alpha subtype D (RIFN alpha D) in reducing HSV-1 shedding.
• To compare different dosing regimens of RIFN alpha D.
• To assess the effect of RIFN alpha D on adrenergically induced and spontaneous HSV-1 shedding.

Main Methods:

• HSV-1 infection was induced in rabbit corneas.
• Viral shedding was induced using 6-hydroxydopamine iontophoresis and topical epinephrine.
• Rabbits were treated with RIFN alpha D or RIFN alpha A at various schedules (two drops QID, one drop BID).
• Tear samples were collected to measure interferon concentration.

Main Results:

• RIFN alpha D significantly reduced HSV-1 shedding when administered at two drops QID, a regimen superior to one drop BID.
• RIFN alpha A also showed effectiveness in reducing viral shedding.
• RIFN alpha D treatment reduced shedding during adrenergically induced episodes but not spontaneous ones.
• Higher interferon concentrations were detected in tears following RIFN alpha D treatment compared to RIFN alpha A.

Conclusions:

• RIFN alpha D is an effective antiviral agent for reducing HSV-1 shedding in rabbit corneas, particularly with a higher frequency dosing schedule.
• The study highlights the potential of RIFN alpha D as a therapeutic option for ocular HSV-1 infections.
• Further research is warranted to explore its efficacy in different shedding scenarios and its pharmacokinetic profile.